Holen Sie sich die Stockscreener-App
0.685
2.22%
0.0149
Schlusskurs vom Vortag:
$0.6701
Offen:
$0.7
24-Stunden-Volumen:
11,874
Relative Volume:
0.11
Marktkapitalisierung:
$2.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.35M
KGV:
-1.4891
EPS:
-0.46
Netto-Cashflow:
$-5.48M
1W Leistung:
-12.78%
1M Leistung:
-23.03%
6M Leistung:
+102.66%
1J Leistung:
+75.64%
1-Tages-Spanne:
$0.685
$0.7299
1-Wochen-Bereich:
$0.6319
$0.798
52-Wochen-Spanne:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Firmenname
Shuttle Pharmaceuticals Holdings Inc
Sektor
Telefon
(240) 403-4212
Adresse
401 PROFESSIONAL DRIVE, GAITHERSBURG
Vergleichen Sie SHPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.685 | 2.79M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Shuttle Pharmaceuticals Holdings Inc Aktie (SHPH) Neueste Nachrichten
Shuttle Pharmaceuticals expands glioblastoma trial - MSN
Form 424B3 Shuttle Pharmaceuticals - StreetInsider.com
BlackRock MuniHoldings New York Quality Fund Enters Standstill Agreement with Saba Capital Management - Defense World
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Shuttle Pharma hits 25% mark in glioblastoma trial - MSN
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug - StockTitan
Form S-1 Shuttle Pharmaceuticals - StreetInsider.com
Shuttle Pharmaceuticals (NASDAQ:SHPH) Faces Potential Delisting from Nasdaq due to Minimum Bid Price Requirement Noncompliance - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - The Manila Times
Shuttle Pharmaceuticals CEO to Present Glioblastoma Trial Updates at Lytham Partners Healthcare Summit - StockTitan
Tilray (TLRY) Stock Drops 5.11% Amidst Market Volatility - GuruFocus.com
EZFill Holdings, Inc. Enters Mobile Fueling Vendor Agreement with Amazon - Defense World
Shuttle Pharmaceuticals Holdings, Inc. Engages in Sponsored Research Agreement with UCSF - Defense World
Shuttle Pharma Enters into Sponsored Research Agreement - GlobeNewswire
Shuttle Pharmaceuticals Partners with UCSF for Breakthrough Prostate Cancer Diagnostic Development - StockTitan
Shuttle Pharmaceuticals stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
SHPH stock touches 52-week low at $0.75 amid market challenges - Investing.com UK
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA - GuruFocus.com
Likelihood of Approval and Phase Transition Success Rate ModelRopidoxuridine in Bile Duct Cancer (Cholangiocarcinoma) - GlobalData
Shuttle Pharmaceuticals Initiates Phase 2 Clinical Trial for Glioblastoma Treatment- - Defense World
Shuttle Pharmaceuticals stock hits 52-week low at $0.83 By Investing.com - Investing.com Canada
Shuttle Pharma Expands Patient Enrollment for Phase 2 - GlobeNewswire
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma - TipRanks
Shuttle Pharmaceuticals Launches Phase 2 Trial for Breakthrough Glioblastoma Treatment | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Up - GuruFocus.com
Micro Cap Company Is Soaring On Phase 2 Trial Update - MSN
500: Something went wrong - Investing.com UK
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Shuttle Pharma Provides Third Quarter 2024 Corporate Update - GlobeNewswire
Shuttle Pharma Advances Phase 2 Trial, Secures $4.5M Funding for Cancer Treatment Study | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals’ $4.5 Million Common Stock Offering - Global Legal Chronicle
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News - MSN
Shuttle Pharma Raises $4.5M for Clinical Trials - TipRanks
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
Shuttle Pharmaceuticals Successfully Doses First Patients in Phase 2 Clinical Trial for Glioblastoma Treatment - Defense World
Shuttle Pharma doses three subjects in Phase II glioblastoma treatment trial - Yahoo! Voices
"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs" - Marketscreener.com
SHPHShuttle Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Shuttle Pharmaceuticals dips 6%, prices $3.5M share offering - MSN
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of - GlobeNewswire
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Benzinga
Shuttle Pharma Pays Off Senior Secured Convertible Note - GlobeNewswire
Finanzdaten der Shuttle Pharmaceuticals Holdings Inc-Aktie (SHPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):